title: Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum.
abstract: BACKGROUND
  Prostate-specific antigen (PSA) occurs in serum both free and in complex with protease inhibitors. The complex with alpha1-antichymotrypsin (ACT) is the major form in serum, and the proportion of PSA-ACT is higher in prostate cancer (PCa) than in benign prostatic hyperplasia (BPH). PSA also forms a complex with alpha1-protease inhibitor (API) in vitro, and the PSA-ACT complex has been detected in serum from patients with prostate cancer. The aim of the present study was to develop a quantitative method for the determination of PSA-API and to determine the serum concentrations in patients with PCa and BPH.
  
  
  METHODS
  The assay for PSA-API utilizes a monoclonal antibody to PSA as capture and a polyclonal antibody to API labeled with a Eu-chelate as a tracer. For calibrators, PSA-API formed in vitro was used. Serum samples were obtained before treatment from 82 patients with PCa, from 66 patients with BPH, and from 22 healthy females.
  
  
  RESULTS
  The concentrations of PSA-API are proportional to the concentrations of total PSA. PSA-API comprises 1.0-7.9% (median, 2.4%) of total immunoreactive PSA in PCa and 1.3-12.2% (median, 3.6%) in BPH patients with serum PSA concentrations >4 microgram/L. In patients with 4-20 microgram/L total PSA, the proportion of PSA-API serum is significantly higher in BPH (median, 4.1%) than in PCa (median, 3. 2%; P = 0.02).
  
  
  CONCLUSIONS
  The proportion of PSA-API in serum is lower in patients with PCa than in those with BPH. These results suggest that PSA-API is a potential adjunct to total and free PSA in the diagnosis of prostate cancer.
authors.affiliation: Departments of Clinical Chemistry, Urology, and Pathology, Helsinki University Central Hospital, FIN-00290 Helsinki, Finland.
authors.forename: W M
authors.initials: WM
authors.lastname: Zhang
authors.forename: P
authors.initials: P
authors.lastname: Finne
authors.forename: J
authors.initials: J
authors.lastname: Leinonen
authors.forename: S
authors.initials: S
authors.lastname: Vesalainen
authors.forename: S
authors.initials: S
authors.lastname: Nordling
authors.forename: U H
authors.initials: UH
authors.lastname: Stenman
mesh_terms: D004591:Electrophoresis, Polyacrylamide Gel; D015200:Fluoroimmunoassay; D006801:Humans; D015151:Immunoblotting; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood; D011485:Protein Binding; D000514:alpha 1-Antichymotrypsin / Q000097:blood / Q000378:metabolism; D000515:alpha 1-Antitrypsin / Q000032:analysis* / Q000378:metabolism
chemical_list: D000514:alpha 1-Antichymotrypsin; D000515:alpha 1-Antitrypsin; D017430:Prostate-Specific Antigen